

Press release

Labomar accelerates in innovation and the development of proprietary technologies: Euro 10 million committed to three-year Research & Development plan


The company introduces its 19th patent at Vitafoods Europe, presenting a game changer in versatility and performance

Bertin: "We are investing to develop cutting-edge solutions that are ready to respond to the challenges of the future."

Istrana (TV), May 15, 2025 - Labomar doubles down on its commitment to innovation and announces a three-year, Euro 10 million plan for Research & Development. The move represents a concrete commitment which seeks, among other things, to accelerate the development of innovative, proprietary technologies that are ready for market. This commitment has now resulted in 19 active patents. The most recent, **Mucowall**, will debut at Vitafoods Europe, one of the leading international events for nutraceuticals, which will take place in Barcelona on May 20-22.

This latest technological milestone is the result of Labomar's strategy of continuous innovation, which is based on an integrated model that includes the company's internal Research & Development department, **Labomar Research** and **Labomar Scientific Service**. The team comprises 20 specialists engaged in creating exclusive formulations, advanced stability protocols and patented technologies that offer high scientific value. This is a distinctive approach that further strengthens the company's positioning as a CDMO* at the forefront of the nutraceutical landscape.

*"I have always believed that R&D is the key to setting Labomar apart in the nutraceutical landscape. From the earliest days of the company, I chose to invest in it, in the conviction that scientific innovation is the real driver of our added value," comments **Walter Bertin**, founder and Chief Executive Officer of Labomar. Today, this division remains the beating heart of our strategy, and our new three-year plan seeks to deliver significant acceleration in the development of proprietary solutions that can respond in a targeted, flexible way to market demands. And that's not all: the versatility of our patented technologies, combined with their high technological value, means we can offer customers cutting-*



edge products that are ready for launch, reducing development times and costs. This constitutes a real advantage for our partners, enabling them to enter specific markets more quickly. For this important new milestone, my thanks go to our team of researchers, whose professionalism and expertise are the real drivers this growth."

The new Mucowall patent represents the fruit of over two years of in-house research carried out by Labomar Scientific Service, a unit that specialises in developing in-vitro pre-clinical tests and laboratory analysis. This division supports the design and planning of innovative solutions in nutraceuticals, medical devices, and cosmetics. Its approach focuses on scientific quality and personalisation, delivering solutions that respond to customer requirements.

Mucowall adheres to mucous membranes, forming a protective barrier that can reduce exposure to irritants and harmful elements. Its applications cover a range of pharmaceutical forms and therapeutic areas. It is a highly innovative solution, a game changer in terms of versatility and performance, delivering improved performance while enhancing **product effectiveness and ease of use**. Thanks to a platform of components that can be integrated and personalised according to different needs, it also enables Labomar customers to **reduce development times**, thereby accelerating **the market entry phase**.

* Contract Development and Manufacturing Organisation.


Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 25 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard.

The Company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Following the acquisitions of Labomar Canada, the Welcare Group and Labiotre Srl, in 2022 Labomar focused on maximising the synergies among the various companies, pooling resources and expertise to expand its product portfolio, enter new markets and streamline certain processes, including through the best practices brought by each of the Group companies.

After a time on the EGM segment of the stock market, which ended in September 2023, Labomar's shareholder structure now includes Charterhouse, one of the oldest private equity firms operating in Europe. This is once again testament to the Company's attention on overseeing the market and planning its growth.



Labomar whole-heartedly believes in a business system based on sustainability and a real concern for people, the environment and the community. It therefore by 2020 had gained Benefit Company status and later obtained B-Corp™ Certification. This is testament to the Company's decision to join a global movement of enterprises meeting elevated social and environmental impact standards.

For further information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Chiara Andretta - +39 3470682566 - chiara.andretta@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it